A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ir-CPI in Healthy Male Subjects

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
The purpose of this First-in-Human study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of Ir-CPI, a novel dual inhibitor of FXIIa and FXIa, following IV administration of single ascending doses in healthy male volunteers.
Epistemonikos ID: 9ad4770342a51f13b3436d996ddab748fd410aee
First added on: May 07, 2024